Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600211's Quick Ratio is ranked better than 73.87% of 999
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs SHSE:600211: 2.77
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Tibet Rhodiola Pharmaceutical Holding Co Quick Ratio Related Terms
Tibet Rhodiola Pharmaceutical Holding Co Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tibet Rhodiola Pharmaceutical Holding Co Quick Ratio Chart
Tibet Rhodiola Pharmaceutical Holding Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Rhodiola Pharmaceutical Holding Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tibet Rhodiola Pharmaceutical Holding Co Quick Ratio vs Drug Manufacturers Industry
Tibet Rhodiola Pharmaceutical Holding Co Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) has a Quick Ratio of 2.77 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. This is near median its historical median of 2.79. Over the past decade, Tibet Rhodiola Pharmaceutical Holding Co's Quick Ratio has ranged from 0.25 to 4.96. According to the industry distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #261 out of 999 companies in the Drug Manufacturers industry, placing it in the top 26.1%.
Is Tibet Rhodiola Pharmaceutical Holding Co's Quick Ratio too high?
Tibet Rhodiola Pharmaceutical Holding Co's current Quick Ratio of 2.77 is near median its 10-year median of 2.79. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 4.96. The Drug Manufacturers industry median Quick Ratio is 1.45. Tibet Rhodiola Pharmaceutical Holding Co's value of 2.77 is 91% above this industry median. Based on the distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #261 out of 999 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Tibet Rhodiola Pharmaceutical Holding Co has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tibet Rhodiola Pharmaceutical Holding Co's Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #261 out of 999 companies for Quick Ratio. This puts Tibet Rhodiola Pharmaceutical Holding Co in the upper half of its industry. The industry median Quick Ratio is 1.45. Tibet Rhodiola Pharmaceutical Holding Co's value of 2.77 is 91% above this benchmark. Historically, Tibet Rhodiola Pharmaceutical Holding Co's own Quick Ratio has ranged from 0.25 to 4.96 over the past decade. While the company's 10-year median is 2.79 vs. the industry median of 1.45, Tibet Rhodiola Pharmaceutical Holding Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 999 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tibet Rhodiola Pharmaceutical Holding Co's current Quick Ratio of 2.77 is 91% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tibet Rhodiola Pharmaceutical Holding Co's current Quick Ratio is 2.77, which is near median its own 10-year median of 2.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tibet Rhodiola Pharmaceutical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) is currently considered Fairly Valued. The stock's GF Value™ is ¥40.53, compared to a current price of ¥39.30 — trading 3% below its estimated fair value. The current Quick Ratio is 2.77, which is near median its 10-year median of 2.79 and 91% above the Drug Manufacturers industry median of 1.45. Tibet Rhodiola Pharmaceutical Holding Co's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211), the current Quick Ratio is 2.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be undervalued.
The current stock price of ¥39.30 is trading 3% below its estimated GF Value™ of ¥40.53.
GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Fairly Valued.
Key valuation signals for SHSE:600211:
Quick Ratio: 2.77 (near median its 10-year median of 2.79)
GF Value™: ¥40.53 vs. price of ¥39.30 (3% below fair value)
Industry Position: 91% above the Drug Manufacturers median (#261 of 999)
No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tibet Rhodiola Pharmaceutical Holding Co Business Description
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
94GF Score
Get the complete analysis for SHSE:600211
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600211 has been successfully added to your 
